IQVIA Holdings Inc. $IQV Stake Lifted by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 174.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,827 shares of the medical research company’s stock after purchasing an additional 8,151 shares during the period. J. Safra Sarasin Holding AG’s holdings in IQVIA were worth $2,891,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Alliancebernstein L.P. raised its stake in shares of IQVIA by 1.2% in the 3rd quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock worth $683,323,000 after buying an additional 41,643 shares in the last quarter. Boston Partners bought a new stake in IQVIA in the third quarter worth about $676,698,000. Artisan Partners Limited Partnership boosted its position in shares of IQVIA by 4.9% during the 3rd quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock valued at $652,246,000 after purchasing an additional 161,085 shares in the last quarter. Invesco Ltd. grew its stake in shares of IQVIA by 15.3% in the 3rd quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock worth $526,891,000 after purchasing an additional 367,204 shares during the last quarter. Finally, Nordea Investment Management AB raised its holdings in shares of IQVIA by 12.3% in the 3rd quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock worth $421,257,000 after purchasing an additional 253,759 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on IQV shares. Citigroup decreased their price target on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Evercore reissued an “outperform” rating and set a $225.00 price objective on shares of IQVIA in a research note on Thursday, February 5th. Mizuho set a $215.00 target price on IQVIA in a report on Monday, February 23rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. decreased their price target on IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $229.13.

IQVIA Trading Up 2.6%

IQVIA stock opened at $170.50 on Wednesday. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a market capitalization of $28.93 billion, a price-to-earnings ratio of 21.69, a P/E/G ratio of 1.60 and a beta of 1.39. The company has a 50 day moving average price of $184.00 and a 200 day moving average price of $205.18.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. The company had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the business earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.